| Apogee Therapeutics: APG808 Asthma Treatment May Overtake Dupixent In IL-4Rα Class |
Apogee Therapeutics, Inc. achieved positive interim results from phase 1b study using APG808 for the treatment of patients with Asthma. Interim 16-week data from the phase 2 APEX study using APG777 for the treatment of patients with AD expected mid-2025. The global asthma treatment market size is projected to reach $35.93 billion by 2034. |
seekingalpha.com |
2025-05-12 20:04:25 |
Czytaj oryginał (ang.) |
| American Power Group Reports 25 Million Cumulative Run Hour Milestone For Its Dual Fuel Stationary/Off-Road Primary Power and Critical Care Emergency Back-Up Power Applications |
ALGONA, IA / ACCESS Newswire / May 12, 2025 / American Power Group Corporation ("APG") (OTC Pink:APGI) the leading U.S. based dual fuel diesel engine conversion technology company today announced the company's stationary/off-road dual fuel installation base has reached an estimated 25 million cumulative run hour milestone. APG's patented Dual Fuel Technology, which converts existing diesel engines to run on up to 65% natural gas, has achieved global market leadership recognition in converting high-horsepower diesel generators and diesel pumps in a variety of key primary power and critical care emergency back-up power market applications such as: *Oil/Gas Operations *Manufacturing Facilities *Hospitals *Data/Blockchain Centers*Frozen Good Warehousing *Peak-Shaving Support *Public/Govt Bldgs *Microgrids APG's S4000 Dual Fuel Technology seamlessly introduces natural gas from renewable, fossil, or treated field gas into the induction system of a diesel engine, displacing up to 65% of the diesel fuel. |
accessnewswire.com |
2025-05-12 13:00:00 |
Czytaj oryginał (ang.) |
| Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma |
Multiple doses of APG808 resulted in rapid suppression of FeNO, a biomarker of Type 2 inflammation associated with exacerbations in asthma, with a robust maximal FeNO decrease from baseline of 53% |
globenewswire.com |
2025-05-12 10:00:00 |
Czytaj oryginał (ang.) |
| 3 Business Services Stocks to Watch in a Prospering Industry |
The Zacks Business Services industry is poised to prosper with rising demand and growing technology adoption. CTAS, APG and BFAM are three stocks that appear well-poised to ride this demand strength. |
zacks.com |
2025-05-08 19:00:35 |
Czytaj oryginał (ang.) |
| APi (APG) Is Up 13.03% in One Week: What You Should Know |
Does APi (APG) have what it takes to be a top stock pick for momentum investors? Let's find out. |
zacks.com |
2025-05-07 17:00:53 |
Czytaj oryginał (ang.) |
| APi Group to Webcast 2025 Investor Day Live on May 21, 2025 |
NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi” or the “Company”) today announced it will webcast its 2025 Investor Day beginning at 9:00 a.m. ET on Wednesday, May 21, 2025. The event should conclude at approximately 12:00 p.m. ET. Presentations by Russell A. Becker, President and Chief Executive Officer; David Jackola, Executive Vice President and Chief Financial Officer; and members of APi's senior leadership team will highlight new, meaningfully higher long-ter. |
businesswire.com |
2025-05-07 11:30:00 |
Czytaj oryginał (ang.) |
| APi Group Corporation (APG) Q1 2025 Earnings Call Transcript |
APi Group Corporation (NYSE:APG ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Adam Fee – Vice President of Investor Relations Russ Becker – President and Chief Executive Officer David Jackola – Executive Vice President and Chief Financial Officer Conference Call Participants Andy Kaplowitz – Citigroup Tim Mulrooney – William Blair Jasper Bibb – Truist Securities Andy Wittmann – Baird Kathryn Thompson – Thompson Research Group Stephanie Moore – Jefferies Steve Tusa – JPMorgan Josh Chan – UBS Jack Cauchi – Barclays Operator Good morning, ladies and gentlemen, and welcome to APi Group's First Quarter 2025 Financial Results Conference Call. All participants are now in a listen-only mode until the question-and-answer session. |
seekingalpha.com |
2025-05-01 19:10:03 |
Czytaj oryginał (ang.) |
| APi (APG) Reports Q1 Earnings: What Key Metrics Have to Say |
While the top- and bottom-line numbers for APi (APG) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-05-01 14:36:27 |
Czytaj oryginał (ang.) |
| APi (APG) Q1 Earnings and Revenues Beat Estimates |
APi (APG) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.34 per share a year ago. |
zacks.com |
2025-05-01 13:45:40 |
Czytaj oryginał (ang.) |
| APi Group Reports First Quarter 2025 Financial Results |
NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi” or the “Company”) today reported its financial results for the three months ended March 31, 2025. Russ Becker, APi's President and Chief Executive Officer stated: “We are off to a strong start in 2025, with a return to traditional levels of organic growth after our thoughtful and selective pruning of certain customer accounts in 2024. We've also continued to expand margins and deploy capital on M&A and share repu. |
businesswire.com |
2025-05-01 11:30:00 |
Czytaj oryginał (ang.) |
| APi Group Confirms Date of First Quarter 2025 Earnings Release |
NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi” or the “Company”) announced today that it intends to release its financial results for the three months ended March 31, 2025, before the market opens on Thursday, May 1, 2025. First Quarter Earnings Conference Call APi will hold a webcast/dial-in conference call to discuss its financial results at 8:30 a.m. (Eastern Time) on Thursday, May 1, 2025. Participants on the call will include Russell A. Becker, President and. |
businesswire.com |
2025-04-17 11:30:00 |
Czytaj oryginał (ang.) |
| Apogee Therapeutics: Engineering Biologic Dominance |
Apogee's strong financial position, with $731.1 million in cash, funds operations through Q1 2028, de-risking its ambitious pipeline development in inflammatory diseases. Significant R&D investments in lead IL-13 inhibitor APG777 and combination therapies reflect a strategic push for differentiated, best-in-class treatments in atopic dermatitis and asthma. Encouraging Phase 1 data for OX40L inhibitor APG990 supports its combination potential with APG777, promising infrequent dosing and broad efficacy in inflammatory diseases. |
seekingalpha.com |
2025-04-14 12:04:40 |
Czytaj oryginał (ang.) |
| APi Group Appoints David Jackola Executive Vice President & Chief Financial Officer |
NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi” or the “Company”) today announced the appointment of David Jackola as Executive Vice President & Chief Financial Officer, effective immediately. Mr. Jackola has been with the Company since October 2021, most recently serving as Interim Chief Financial Officer since December of 2024. He will report directly to Russ Becker, President and Chief Executive Officer of APi. Russ Becker, APi's President and Chief Executi. |
businesswire.com |
2025-03-31 11:30:00 |
Czytaj oryginał (ang.) |
| APi Group Announces Participation in the 2025 J.P. Morgan Industrials Conference |
NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi”) today announced that its senior leadership will be participating in a fireside chat during the 2025 J.P. Morgan Industrials Conference on Wednesday, March 12th at 10:30 a.m. ET. A live webcast link and archived replay will be available in the “Events” area on the Investor Relations page of APi's website at www.apigroupcorp.com. Interested parties should check the Company's website for any schedule updates or time ch. |
businesswire.com |
2025-03-07 09:30:00 |
Czytaj oryginał (ang.) |
| APi Group: Rating Downgrade As I Am Not Confident On FY25 Performance |
I am downgrading APi Group (APG) to hold due to uncertain near-term performance, weak organic growth, and macro uncertainties impacting FY25 outlook. Despite solid 4Q24 adj EBITDA growth and a healthy backlog, APG's organic growth remains weak, particularly in the Specialty Services segment. APG's transition to high-margin ISM revenue is positive, but near-term organic growth concerns and potential macro risks could pressure the stock. |
seekingalpha.com |
2025-03-04 11:23:49 |
Czytaj oryginał (ang.) |
| Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990) |
Interim Phase 1 results for APG990, a novel half-life extended OX40L antibody, exceeded trial objectives and demonstrated an approximately 60-day half-life |
globenewswire.com |
2025-03-03 08:00:00 |
Czytaj oryginał (ang.) |
| Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025 |
SAN FRANCISCO and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced it will report interim results from the Phase 1 APG990 healthy volunteer trial on Monday, March 3, 2025. Following the announcement, the Company will host a conference call and webcast at 8:30am ET to discuss the results and plans for its combination approach for APG777 + APG990. |
globenewswire.com |
2025-02-28 18:00:00 |
Czytaj oryginał (ang.) |
| APi Group Corporation (APG) Q4 2024 Earnings Call Transcript |
APi Group Corporation (NYSE:APG ) Q4 2024 Earnings Conference Call February 26, 2025 8:30 AM ET Company Participants Adam Fee - Vice President, Investor Relations Russell Becker - President and Chief Executive Officer David Jackola - Interim Chief Financial Officer Conference Call Participants David Paige - RBC Capital Markets Kathryn Thompson - Thompson Research Group Tim Mulrooney - William Blair Josh Chan - UBS Harold Antor - Jefferies Andy Wittmann - Baird Jon Tanwanteng - CJS Securities Operator Good morning, ladies and gentlemen, and welcome to APi Group's Fourth Quarter and Full-Year 2024 Financial Results Conference Call. All participants are in a listen-only mode until the question-and-answer session. |
seekingalpha.com |
2025-02-26 17:10:05 |
Czytaj oryginał (ang.) |
| APi (APG) Reports Q4 Earnings: What Key Metrics Have to Say |
The headline numbers for APi (APG) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-02-26 12:36:21 |
Czytaj oryginał (ang.) |
| APi (APG) Q4 Earnings and Revenues Beat Estimates |
APi (APG) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.44 per share a year ago. |
zacks.com |
2025-02-26 11:45:30 |
Czytaj oryginał (ang.) |
| APi Group Reports Fourth Quarter and Full Year 2024 Financial Results |
NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi” or the “Company”) today reported its financial results for the three months and full year ended December 31, 2024. Russ Becker, APi's President and Chief Executive Officer stated: “Our record results in 2024 once again demonstrate the strength of our recurring revenue, services-focused business model and the ongoing execution of our strategy by our teammates. We begin 2025 with positive momentum and the demand for th. |
businesswire.com |
2025-02-26 09:30:00 |
Czytaj oryginał (ang.) |
| Oldcastle APG Showcases Complete Product Portfolio at International Builders' Show |
ATLANTA--(BUSINESS WIRE)--Oldcastle APG, the leading provider of outdoor living solutions in North America, will share its latest product innovations and solutions at the 2025 NAHB International Builders' Show taking place in Las Vegas, Nev., from February 25 – 27. Oldcastle APG will feature its complete line of outdoor living brands that provide homeowners and building professionals with the products they need to effortlessly create beautiful outdoor spaces for customers to Live Well Outside™. |
businesswire.com |
2025-02-21 19:47:00 |
Czytaj oryginał (ang.) |
| APi Group Provides Update on 2024 Performance and Initial 2025 Guidance and Announces Repricing of Term Loan |
NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi” or the “Company”) today provided an update on year-end 2024 results and net revenue and adjusted EBITDA guidance for 2025. The Company also announced the successful repricing of its Term Loan due 2029. The Company is participating in two upcoming investor conferences and may discuss these items while at the conferences. Financial Update Russ Becker, APi's President and Chief Executive Officer stated: “I want to thank. |
businesswire.com |
2025-02-19 09:30:00 |
Czytaj oryginał (ang.) |
| APi Group Confirms Date of Fourth Quarter 2024 Earnings Release and Announces Participation in Upcoming Investor Conferences |
NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi”) announced today that it intends to release its financial results for the three months and full year ended December 31, 2024, before the market opens on Wednesday, February 26, 2025. Fourth Quarter Earnings Conference Call APi will hold a webcast/dial-in conference call to discuss its financial results at 8:30 a.m. (Eastern Time) on Wednesday, February 26, 2025. Participants on the call will include Russell A. Becker. |
businesswire.com |
2025-02-05 09:30:00 |
Czytaj oryginał (ang.) |
| Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis |
Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled Part A 16-week proof-of-concept data anticipated in mid-2025 SAN FRANCISCO and BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis (EoE) and other I&I indications, today announced the first patient has been dosed in the Part B portion of the Phase 2 APEX clinical trial of APG777 in patients with moderate-to-severe AD, as well as enrollment completion in the Part A portion of the trial. “Enrollment for the Phase 2 Part A trial of APG777 surpassed the approximately 110 patient target ahead of schedule, driven by strong patient and investigator enthusiasm, underscoring the potential of APG777 to address the need for safe, effective treatment options that reduce injection burden and provide better disease control for patients with AD and other I&I conditions,” said Carl Dambkowski, M.D. |
globenewswire.com |
2025-02-03 09:00:00 |
Czytaj oryginał (ang.) |
| Oldcastle® APG Announces Launch of Catalyst™ Fence Solutions |
ATLANTA--(BUSINESS WIRE)--Oldcastle® APG, a CRH company, announces the launch of Catalyst™ Fence Solutions, its flagship fence brand. |
businesswire.com |
2025-01-14 13:04:00 |
Czytaj oryginał (ang.) |
| APi Group: Expecting Growth To Accelerate And Adj EBITDA Margin To Expand |
I reiterate a buy rating for APG due to strong market share potential, growth acceleration, and adj EBITDA margin expansion prospects for FY25 and beyond. APG's solid demand trend is evidenced by a $3.5 billion backlog, robust end markets, and a promising M&A pipeline, ensuring high-single-digit growth. Despite FY24 revenue guidance revision, project delays are temporary, setting up FY25 for stronger growth with positive proposal activity trends. |
seekingalpha.com |
2024-12-18 05:19:31 |
Czytaj oryginał (ang.) |
| APi Group Announces May 2025 Investor Update Meeting and Reiterates FY 2024 Guidance |
NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi” or the “Company”) today announced it will host an Investor Day on Wednesday, May 21, 2025, in New York City. The Company will share more details about the location, participants and webcast details in the coming months. Russ Becker, APi's President and Chief Executive Officer stated: “As we progress towards year end of 2024, I want to thank all of our leaders for their contributions to APi. With record net revenues,. |
businesswire.com |
2024-12-17 09:30:00 |
Czytaj oryginał (ang.) |
| Pattern Energy Announces Equity Investment from Consortium Headed by APG and ART |
SAN FRANCISCO--(BUSINESS WIRE)--Pattern Energy Group LP (Pattern Energy), a leader in renewable energy and transmission infrastructure, today announced that a consortium, headed by APG Asset Management N.V. (APG), on behalf of the largest Dutch pension fund, ABP, and Australian Retirement Trust (ART), will acquire Riverstone Holdings LLC's (Riverstone) equity stake in the company, becoming owners alongside Canada Pension Plan Investment Board (CPP Investments) and Pattern management. The transa. |
businesswire.com |
2024-12-16 09:30:00 |
Czytaj oryginał (ang.) |
| APi Group Announces Participation in the UBS Global Industrials and Transportation Conference |
NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi” or the “Company”) today announced that its senior leadership will be participating in a fireside chat during the UBS Global Industrials and Transportation Conference on Wednesday, December 4th at 9:40 a.m. ET. A live webcast link and archived replay will be available in the “Events” area on the Investor Relations page of APi's website at www.apigroupcorp.com. Interested parties should check the Company's website for. |
businesswire.com |
2024-11-26 09:30:00 |
Czytaj oryginał (ang.) |
| APi Group Announces CFO Transition |
NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi” or the “Company”) today announced that Kevin Krumm, Chief Financial Officer, will step down from his role on December 13, 2024, to accept another opportunity. David Jackola, current Chief Financial Officer and Vice President of Transformation at APi International, will assume the role of interim Chief Financial Officer upon Krumm's departure and until a successor is appointed. Jackola is a seasoned senior finance exe. |
businesswire.com |
2024-11-22 09:30:00 |
Czytaj oryginał (ang.) |
| Building Industry Partners Announces Strategic Sale of Rapidly Growing Endeavor Fire Protection to APi Group Corporation |
BOSTON--(BUSINESS WIRE)--Building Industry Partners (“BIP”), the leading middle market private equity firm focused on the U.S. building industry, is proud to announce the successful sale of Endeavor Fire Protection (“Endeavor”), a rapidly growing provider of fire protection and life safety installation, maintenance and repair, and inspection services. Endeavor was sold to APi Group Corporation (NYSE: APG) (“APi”), a market-leading publicly traded provider of business services, including safety. |
businesswire.com |
2024-11-20 17:43:00 |
Czytaj oryginał (ang.) |
| Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis |
Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing and potential applications in asthma, COPD, and psoriasis. APGE's investigational pipeline includes APG808 and APG990, targeting different inflammatory pathways, enhancing its potential in the I&I market. APGE's strong cash runway and multiple upcoming catalysts, including Phase 2 results for APG777, justify its current valuation premium. |
seekingalpha.com |
2024-11-10 11:55:15 |
Czytaj oryginał (ang.) |
| APi Group Corporation (APG) Q3 2024 Earnings Call Transcript |
APi Group Corporation (NYSE:APG ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Adam Fee - VP, IR Russell Becker - President and CEO Kevin Krumm - EVP and CFO Conference Call Participants Kenyon Pelletier - Barclays Stephanie Moore - Jefferies Andy Wittmann - Baird Kathryn Thompson - Thompson Research Group Andy Kaplowitz - Citigroup Josh Chan - UBS Jon Tanwanteng - CJS Securities Operator Good morning, ladies and gentlemen and welcome to APi Group's Third Quarter 2024 Financial Results Conference Call. All participants are now in a listen-only mode until the question-and-answer session. |
seekingalpha.com |
2024-11-01 08:42:07 |
Czytaj oryginał (ang.) |
| APi (APG) Meets Q3 Earnings Estimates |
APi (APG) came out with quarterly earnings of $0.51 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.48 per share a year ago. |
zacks.com |
2024-10-31 11:40:31 |
Czytaj oryginał (ang.) |
| APi Group Reports Third Quarter 2024 Financial Results |
NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi” or the “Company”) today reported its financial results for the three and nine months ended September 30, 2024. Russ Becker, APi's President and Chief Executive Officer stated: “The team's work over the last few years executing our strategy has resulted in APi being the strongest it has ever been with 2024 shaping up to be a year of record net revenues, margins and free cash flow generation. As we plan for a return to. |
businesswire.com |
2024-10-31 09:30:00 |
Czytaj oryginał (ang.) |
| Genuine Parts Company: Rating Downgrade On Weak Near-Term Outlook |
I downgrade Genuine Parts Company stock from buy to hold due to poor 3Q24 performance and a weak macroeconomic outlook impacting both APG and IPG segments. 3Q24 results showed disappointing comparable sales growth, with APG and IPG segments underperforming, leading to a significant miss on EPS estimates. The outlook remains bleak, with no signs of improvement in consumer spending and industrial production. |
seekingalpha.com |
2024-10-24 15:42:58 |
Czytaj oryginał (ang.) |
| APi (APG) Reports Next Week: Wall Street Expects Earnings Growth |
APi (APG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-24 15:06:33 |
Czytaj oryginał (ang.) |
| Is the Options Market Predicting a Spike in APi Group (APG) Stock? |
Investors need to pay close attention to APi Group (APG) stock based on the movements in the options market lately. |
zacks.com |
2024-10-22 14:11:06 |
Czytaj oryginał (ang.) |
| Bet on These 5 Top-Ranked Stocks With Rising P/E |
Pick five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Strategic Education (STRA), KBR (KBR), Super Micro Computer (SMCI), Okta (OKTA) and APi Group (APG). |
zacks.com |
2024-10-22 13:00:27 |
Czytaj oryginał (ang.) |
| APi Group Confirms Date of Third Quarter 2024 Earnings Release |
NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi”) announced today that it intends to release its financial results for the three and nine months ended September 30, 2024, before the market opens on Thursday, October 31, 2024. Third Quarter Earnings Conference Call APi will hold a webcast/dial-in conference call to discuss its financial results at 8:30 a.m. (Eastern Time) on Thursday, October 31, 2024. Participants on the call will include Russell A. Becker, Preside. |
businesswire.com |
2024-10-17 11:30:00 |
Czytaj oryginał (ang.) |
| APi Price And Earnings Diverge, Setting Up Strong Buy Rating |
APi Group Corporation's earnings are set to grow in Q3 and Q4 2024, despite a recent decline in share price, presenting a Strong Buy opportunity. The company's 13/60/80 framework aims to boost adjusted EBITDA margins, recurring revenue, and free cash flow conversion. APi's aggressive acquisition strategy, including the recent purchase of Elevated Facility Services Group, supports its growth and expansion goals. |
seekingalpha.com |
2024-10-15 07:19:49 |
Czytaj oryginał (ang.) |
| Doral Renewables LLC Announces Closing of $400 Million Equity Investment from APG |
PHILADELPHIA, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Doral Renewables LLC (”Doral Renewables” or “the Company”), a leading U.S. developer, owner, and operator of renewable energy and storage projects, announced today the closing of a $400 million minority equity investment by Dutch pension APG on behalf of the largest Dutch pension fund ABP. The investment by and partnership with APG will accelerate the development and construction of Doral Renewables' energy pipeline. As part of the transaction, APG will also provide its pro rata share of corporate credit support and funding for the Company's business up to an additional $185 million of capital over time. |
globenewswire.com |
2024-09-13 11:00:00 |
Czytaj oryginał (ang.) |
| Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases |
Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2025 Initiation of the first clinical trial of APG777 and APG990 combination expected to commence in 2025 with the potential for greater efficacy in atopic dermatitis and across I&I diseases SAN FRANCISCO and WALTHAM, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that it has initiated dosing of healthy volunteers in its first clinical trial for APG990, a novel, subcutaneous (SQ) half-life extended monoclonal antibody targeting OX40L, which is being developed initially as a treatment for people living with AD. |
globenewswire.com |
2024-08-19 11:00:00 |
Czytaj oryginał (ang.) |
| Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results |
Continued advancement of pipeline and execution towards expected milestones, including APG777 16-week proof-of-concept data from the Phase 2 Part A trial in 2H 2025, APG808 interim Phase 1 data in 4Q 2024, and APG990 Phase 1 trial initiation in healthy volunteers accelerated to 3Q 2024 |
globenewswire.com |
2024-08-12 10:30:00 |
Czytaj oryginał (ang.) |
| American Power Group Announces $800,000 of S4000 Stationary Dual Fuel Systems Orders |
- Over 325 Diesel Frac Engines/Pumps Converted to APG's Dual Fuel Technology to Date - ALGONA, IA / ACCESSWIRE / August 6, 2024 / American Power Group Corporation ("APG") (OTC Pink:APGI) announced today that it has received approximately $2.2 million of follow-on orders since October 1st from its network of stationary certified dealer/installers with approximately $800,000 received and to be shipped in the September 4th fiscal quarter. Fiscal 2024 YTD revenue is approximately $2.9 million which is over 230% higher than all of fiscal 2023 and attributable to stronger dual fuel stationary conversion revenue. |
accesswire.com |
2024-08-06 13:00:00 |
Czytaj oryginał (ang.) |